PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2024
0mins
Should l Buy ?
Source: newsfilter
- Urgent Request for IV Suramin: PaxMedica Inc. is responding to an urgent request from the Ministry of Health of Malawi for IV suramin to combat sleeping sickness in the region.
- PaxMedica's Response: The Chairman and CEO, Howard Weisman, highlights the company's commitment to providing immediate assistance by granting access to PAX-101 within 30 days.
- Completion of Registration Batches: PaxMedica recently completed three pivotal registration/validation batches of PAX-101 for treating Trypanosoma brucei rhodesiense.
- About PaxMedica: The company specializes in anti-purinergic drug therapies for neurological disorders, focusing on conditions like Autism Spectrum Disorder (ASD) and aims to provide a reliable source of suramin.
- Forward-Looking Statements: The press release includes forward-looking statements about the company's clinical program, trials, regulatory filings, and risks associated with development work.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
